has announced the issuance of US Patent No. 12,134,635 covering its two new drug candidates, SON-1411 and SON-1400, expected to advance treatment options for cancer. The patent, titled ‘Interleukin 18 (IL-18) Variants and Fusion Proteins Comprising Same’ was issued by the US Patent and Trademark Office.
The gold standard of business intelligence. The drug candidates comprise modified versions of recombinant human interleukin-18 with the patent effective till June 2044. SON-1411 is a bifunctional fusion protein that combines IL-18 with single-chain wild-type IL-12, connected to the company’s Fully Human Albumin Binding (FHAB) platform.
Another drug, SON-1400 is a monofunctional fusion protein comprising the FHAB-connected IL-18 domain. Sonnet founder and CEO Pankaj Mohan said: “The issuance of this intellectual property is an important milestone that we believe provides significant differentiation from competitors trying to tap the full biological potential of IL-18, either alone or in combination with IL-12. Access the most comprehensive Company Profiles on the market, powered by GlobalData.
Save hours of research. Gain competitive edge. Your download email will arrive shortly We are confident about the unique quality of our Company Profiles.
However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form “IL-18 is a key cytokine that, when combined synergistically with IL-12, .
